Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Nobelpharma Makes Global Debut with US Launch of Hyftor
September 1, 2022
- BMS, Nagoya University Tie Up for Innovative Drug Discovery
August 31, 2022
- Eisai Files New Injection Formulation of Fycompa in Japan
August 31, 2022
- Novo Seeks Japan Approval of Hemophilia Drug Concizumab
August 31, 2022
- Viatris Launches Japan PIII to Add GAD Indication for Effexor SR
August 31, 2022
- Taiho’s GIST Drug Jeselhy Now Available in Japan
August 31, 2022
- Daiichi Sankyo Files Vanflyta for Frontline AML in Japan
August 31, 2022
- Stelues Shipments to Get Back to Normal in September: Pfizer Japan
August 30, 2022
- Kymriah Now Approved for Follicular Lymphoma in Japan: Novartis
August 29, 2022
- Minomycin Supply Resumption to Be Delayed: Pfizer
August 26, 2022
- Pfizer Files Ritlecitinib for Alopecia Areata Treatment in Japan
August 26, 2022
- Meiji Pharma in Talks on Japan Rights to Arcturus’ COVID Jab Candidate
August 26, 2022
- Eisai, US Brain Health Diagnostics Provider Seal MOU to Boost Awareness, Development of Blood-Based Assays
August 25, 2022
- Sawai Breaks Ground on New Factory Building in Kyushu, Shipment Start Set for April 2024
August 24, 2022
- Sawai Chief Wants Expert Panel to Discuss Delisting of Generics Deemed No Longer Necessary
August 24, 2022
- Pfizer Continues to Halt Champix Shipments on Prolonged Fix of Manufacturing Process
August 24, 2022
- Takeda’s Dengue Vaccine Gets Its 1st Approval in Indonesia
August 24, 2022
- Daiichi Sankyo’s Quizartinib Accepted for European Review in 1st Line AML
August 24, 2022
- BMS Wants to Jolt Cancer Care Landscape with Broader I/O Combo Options, Pursuing LAG-3 Inhibitor in Japan Too
August 24, 2022
- All Companies Curbing Shipments of Meropenem, Top-Priority Drug Requiring Stable Supplies
August 23, 2022
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…